News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

E. Dühmke

Articles by E. Dühmke

2 Cycles of ABVD Plus Radiotherapy Is More Effective Than Radiotherapy Alone in Early Stage HD-Interim Ahan Radiotherapy Alone in Early Stage HD-Interim Analysis of the HD7 Trial of the GHSG Clinic of Internal Medicine I University of Cologne/Germany

ByH. Tesch,M. Sieber,J. U. Rüffer,J. Franklin,R. Herrmann,F. Boissevain,A. Franke,M. Pfreundschuh,D. Hossfeld,E. Dühmke,J. Wolf,A. Engert,U. Paulus,V. Diehl

March 1st 1999

BACKGROUND: Extended-field radiotherapy is effective in patients with early-stage Hodgkin’s disease, and more than

Increased Efficacy Through Moderate Dose Escalation of Chemotherapy: Interim Report From the HD9 Randomized Trial for Advanced Hodgkin’s Disease

ByV. Diehl,J. Franklin,M. Sieber,D. Hasenclever,U. Paulus,H. Tesch,M. Pfreundschuh,U. Rüffer,R. Hermann,C. Longin,M. Hänel,G. Wulf,W. Aulitzky,A. Georgii,E. Dühmke,M. Loeffler

March 1st 1999

This report aims to assess the effect of increased drug dose on the efficacy and toxicity of the BEACOPP regimen with

Latest Updated Articles

Trending on CancerNetwork

MYTHIC Trial Demonstrates Efficacy in Platinum-Resistant Ovarian Cancer

Novel HP1K Inhibitor Shows Favorable Responses in ccRCC, Solid Tumors

FDA Grants RMAT Designation to RZ-001 in Advanced Hepatocellular Carcinoma

119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Breast Cancer (ABC) Treated With Ribociclib (RIB) + Fulvestrant (FUL): A Subgroup Analysis of Patients With Invasive Lobular Carcinoma (ILC)

Daraxonrasib Shows Antitumor Activity in Pretreated RAS+ Pancreatic Cancer